Bet on teams before science: Third Rock's Chris Robinson on building biotech companies

Key points

Key takeaways from a Talent Take Five interview with Chris Robinson, chief talent officer at Third Rock Ventures (October 2025):

Bet on teams before science. Robinson argues the best ideas are matured by the best teams: Third Rock has launched 70 companies on $4.3bn raised, and he has worked on over 100 project teams and been involved in 65 of the firm's 70 launches, finding that its most cohesive teams produced the better outcomes.

An industry in constriction. After a bull-market decade, drug development still costs roughly $2bn and 10–12 years per approval with a ~90% failure rate; around 200 public biotechs now trade below cash (negative enterprise value), and Robinson suggests the ~900 public biotechs is closer to 500 too many.

Fixation on technical capability is the top hiring fault. Founders recruit experts from renowned labs with Nature or Science papers and overlook leadership ability, leaving people who believe they know more than everyone else and cannot build or inspire a company.

Leaders for war, not peace. In a wartime fundraising climate, Robinson hires for grit, resilience and a 'make it happen' attitude over credentials, and insists companies should right-size on data rather than on available capital.

Starters are not finishers. The originators who get the science right often lack the skills to take a company through clinical and commercial stages; hanging on too long holds growth back, so founders need realistic self-reflection and to hand over the reins.

Trust and the first 20 employees. Culture is set by the earliest hires and is hard to change later; trust cannot be taught or faked, so Third Rock's 'group genius' think-tank model emphasises productive debate among people willing to be challenged.

Mark Levin's leadership test. A sign of a great leader is willingness to hire people who can run each race faster than you, then managing, inspiring and setting strategic direction rather than doing their jobs — and not being the smartest person in the room.

AI in recruiting, human at the edges. AI will transform parts of talent acquisition, but senior biotech hiring will keep leaning on human judgement and connection, especially as companies launch and scale management teams.

Read more: Talent Take Five with Andrew Sterling · Third Rock Ventures